Prognostic value of atn alzheimer biomarkers: 60-month follow-up results from the argentine alzheimer's disease neuroimaging initiative

Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) cohort. Methods: Twenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (...

Full description

Autores:
Allegri, Ricardo F
Méndez, Patricio Chrem
Calandri, Ismael
Cohen, Gabriela
Martín, Maria Eugenia
Russo, María Julieta
Crivelli, Lucia
Pertierra, Lucia
Tapajóz, Fernanda
Clarens, María Florencia
Campos, Jorge
Nahas, Federico E
Vázquez, Silvia
Surace, Ezequiel
Sevlever, Gustavo
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/8236
Acceso en línea:
https://hdl.handle.net/11323/8236
https://doi.org/10.1002/dad2.12026
https://repositorio.cuc.edu.co/
Palabra clave:
Alzheimer's disease
amyloid
biomarkers
classification
neurodegeneration
tau
Rights
openAccess
License
Attribution-NonCommercial-NoDerivatives 4.0 International
Description
Summary:Purpose: To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) cohort. Methods: Twenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (Aβ; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] Aβ42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan). Results: A+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control subjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of mild dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion rates to dementia after 5-year follow-up were 85% in A+T+N+ MCI patients and 50% in A-T-N+ patients. Conclusions: We present initial 5-year follow-up results of a regional ADNI based on AD biomarkers and the ATN classification.